Odds ratio of 6.30 for Guillain-Barré syndrome association with SARS-CoV-2 infection and 0.41 for COVID-19 vaccine administration
No Increase in GBS Seen After COVID-19 Vaccination in Adults
Reporting rate of Guillain-Barré syndrome higher compared with other vaccinations, but rate within incidence range for general population
Peripheral Neuropathy Observed in Patients With ‘Long COVID’
Prolonged small-fiber neuropathy after mild infection most common scenario in small sample of referred patients with WHO-defined long COVID
AAN: Tic Severity in Teens Tied to Social Media Use During Pandemic
Increased use of social media during the COVID-19 pandemic reported in small survey of adolescents with tic disorders
Guillain-Barré Syndrome May Be Triggered by SARS-CoV-2 Infection
During study period, 22 percent with GBS had confirmed or probable SARS-CoV-2 infection; patients had uniform neurologic features
Risk for Bell Palsy Up 42 Days After First Dose of CoronaVac
Hong Kong study shows small increased risk after Sinovac Biotech vaccine, but no significantly increased risk after BNT162b2 vaccine
AAO-HNS Issues Guidance for Bell’s Palsy Treatment During COVID-19
Corticosteroid therapy and/or antiherpes viral therapy recommended for patients developing Bell’s palsy after vaccination